Quest Diagnostics Inc vs Invesco Solar ETF — how do they compare? Quest Diagnostics Inc trades at $205.45 (market cap $22.80B), while Invesco Solar ETF trades at $55.17. The key difference: Quest Diagnostics Inc pays a 1.67% dividend while Invesco Solar ETF pays none, and Quest Diagnostics Inc is trading nearer its 52-week high, Invesco Solar ETF nearer its low. Which is the better fit depends on your goals.
| DGX | TAN | |
|---|---|---|
Market Cap | $22.80B | — |
Sector | Health | Sector/Thematic |
52-Week High | $216.02 | $73.95 |
52-Week Low | $166.42 | $36.07 |
Enterprise Value | $28.82B | — |
Dividend Yield | 1.67% | — |
Signals from Pluang's Aura AI — not financial advice
Quest Diagnostics (DGX) trades at $207.35, showing minimal daily movement with a slight decline of 0.04%. The stock maintains a bullish technical stance with recent earnings beats and analyst consensus pointing to upside potential. Recent developments include New York State approval for Haystack MRD testing and strong momentum across diagnostic channels. Revenue growth accelerated to $11.04 billion in 2025 with consistent profitability margins around 9%.
DGX presents a balanced investment case with 38% analyst buy ratings and a $227.75 price target suggesting 10% upside. The company demonstrates steady revenue growth and operational efficiency, though elevated debt levels and policy risks require monitoring. Second quarter earnings on July 23, 2026, will be crucial for validating current momentum and growth trajectory.
Invesco Solar ETF (TAN) trades at $53.12, down 3.35% amid a bearish technical signal with 18 sell indicators. The fund focuses on utility-scale solar and grid technology, benefiting from AI-driven electricity demand but facing headwinds from policy uncertainty and supply chain costs. Recent news highlights both long-term growth potential and near-term volatility.
Outlook is mixed: strong structural demand for clean energy supports long-term growth, but regulatory risks and technical weakness pose challenges. Investors should weigh exposure to solar's AI-driven expansion against policy sensitivity and current bearish momentum.
Trailing returns across standard periods
Quest Diagnostics is a leading independent provider of diagnostic testing, information, and services in the U.S. The company generates over 95% of its revenue through clinical testing, anatomic pathology, esoteric testing, and substance abuse testing with specimens collected at its national network of roughly 2,300 patient service centers, as well as multiple doctors offices and hospitals. The firm also runs a much smaller diagnostic solutions segment that provides clinical trials testing, risk assessment services, and information technology solutions.
Read more on DGX →TAN is a thematic ETF that tracks the MAC Global Solar Energy Index. It provides targeted exposure to the global solar industry, including manufacturers of solar panels, installers, and component suppliers like Enphase and First Solar.
Read more on TAN →